Two Months On, U.S. DOJ Withdraws Motion Against Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Two months after filing a motion to enforce subpoenas against Indian drug maker Ranbaxy, the U.S. Department of Justice has withdrawn from taking further action. "The DOJ expressed its satisfaction with the documents submitted by Ranbaxy and Parexel Consulting," a source familiar with the issue informed PharmAsia News.
You may also be interested in...
Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA
Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA
Ranbaxy Files For Phase I Trial On First Compound From GSK Deal
MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials